• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices.白细胞介素23在系统性红斑狼疮患者中的意义:与疾病活动和损伤指标的关系。
Biologics. 2023 Jan 18;17:1-9. doi: 10.2147/BTT.S389021. eCollection 2023.
2
Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.血清白细胞介素-34 水平升高与青少年系统性红斑狼疮及疾病活动相关。
Clin Rheumatol. 2020 May;39(5):1627-1632. doi: 10.1007/s10067-019-04899-2. Epub 2020 Jan 6.
3
Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.系统性红斑狼疮中信号素5A升高与疾病活动及狼疮性肾炎相关。
Clin Exp Immunol. 2017 May;188(2):234-242. doi: 10.1111/cei.12924. Epub 2017 Feb 17.
4
Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.埃及女性系统性红斑狼疮患者的血清新蝶呤、肿瘤坏死因子-α及可溶性肿瘤坏死因子受体II(p75)水平与疾病活动度
Clin Biochem. 2005 Feb;38(2):134-41. doi: 10.1016/j.clinbiochem.2004.11.002.
5
Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients.白细胞介素-34、α-干扰素和λ1-干扰素对埃及系统性红斑狼疮患者疾病活动的影响
Reumatologia. 2020;58(4):221-230. doi: 10.5114/reum.2020.98434. Epub 2020 Aug 31.
6
Evaluation of Serum β2-microglobulin in Egyptian Patients with Systemic Lupus Erythematosus.埃及系统性红斑狼疮患者血清β2-微球蛋白的评估
Egypt J Immunol. 2019 Jul;26(2):143-153.
7
Changes of Serum IL-6, IL-17, and Complements in Systemic Lupus Erythematosus Patients.系统性红斑狼疮患者血清白细胞介素-6、白细胞介素-17 和补体的变化。
J Interferon Cytokine Res. 2019 Jul;39(7):410-415. doi: 10.1089/jir.2018.0169. Epub 2019 Jun 7.
8
Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus.血清尿酸作为埃及系统性红斑狼疮患者肾炎的预测因子。
Lupus. 2021 Mar;30(3):378-384. doi: 10.1177/0961203320979042. Epub 2020 Dec 15.
9
Angiotensin-converting enzyme (ACE) serum levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus.埃及系统性红斑狼疮患者的血管紧张素转换酶(ACE)血清水平和基因多态性。
Lupus. 2012 Jan;21(1):103-10. doi: 10.1177/0961203311418268. Epub 2011 Oct 5.
10
Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.白细胞介素-32γ:可能与系统性红斑狼疮患者肾炎的活动和发展有关。
Int J Rheum Dis. 2019 Jul;22(7):1305-1311. doi: 10.1111/1756-185X.13550. Epub 2019 Apr 3.

引用本文的文献

1
Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.系统性红斑狼疮中的免疫细胞异常:靶向治疗走向精准管理
Cell Mol Biol Lett. 2025 Jun 16;30(1):73. doi: 10.1186/s11658-025-00749-z.
2
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review.用于治疗系统性红斑狼疮的单克隆抗体的当前应用与发展:综述
Antib Ther. 2024 Dec 26;8(1):47-55. doi: 10.1093/abt/tbae033. eCollection 2025 Jan.
3
Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.古塞库单抗治疗活动性狼疮性肾炎患者的疗效和安全性:一项2期随机安慰剂对照研究的结果
Rheumatology (Oxford). 2025 May 1;64(5):2731-2740. doi: 10.1093/rheumatology/keae647.
4
Biomarkers for systemic lupus erythematosus: A scoping review.系统性红斑狼疮的生物标志物:系统评价。
Immun Inflamm Dis. 2024 Oct;12(10):e70022. doi: 10.1002/iid3.70022.

本文引用的文献

1
Serum cytokines to predict systemic lupus erythematosus clinical and serological activity.血清细胞因子预测系统性红斑狼疮的临床和血清学活动。
Clin Transl Sci. 2022 Jul;15(7):1676-1686. doi: 10.1111/cts.13283. Epub 2022 May 4.
2
Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis.白细胞介素-17/23阻断疗法治疗狼疮性肾炎的当前证据
Cureus. 2021 Dec 1;13(12):e20087. doi: 10.7759/cureus.20087. eCollection 2021 Dec.
3
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.乌司奴单抗治疗活动性系统性红斑狼疮患者的疗效和安全性:一项开放标签扩展研究的结果。
J Rheumatol. 2022 Apr;49(4):380-387. doi: 10.3899/jrheum.210805. Epub 2021 Dec 1.
4
Secukinumab on Refractory Lupus Nephritis.司库奇尤单抗治疗难治性狼疮性肾炎
Cureus. 2021 Aug 15;13(8):e17198. doi: 10.7759/cureus.17198. eCollection 2021 Aug.
5
IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis.IL-23/IL-17 轴在系统性红斑狼疮和类风湿关节炎发病机制及治疗中的作用。
Malays J Pathol. 2020 Dec;42(3):333-347.
6
Interleukin 23 is elevated in the serum of patients with SLE.白细胞介素 23 在系统性红斑狼疮患者的血清中升高。
Lupus. 2020 Dec;29(14):1943-1947. doi: 10.1177/0961203320952841. Epub 2020 Aug 24.
7
Inflammatory markers in systemic lupus erythematosus.系统性红斑狼疮中的炎症标志物。
J Autoimmun. 2020 Jun;110:102374. doi: 10.1016/j.jaut.2019.102374. Epub 2019 Dec 4.
8
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.在一项针对活动性系统性红斑狼疮患者的为期一年的、多中心、前瞻性、随机、双盲、安慰剂对照交叉试验中,乌司奴单抗的疗效和安全性得到维持。
Arthritis Rheumatol. 2020 May;72(5):761-768. doi: 10.1002/art.41179. Epub 2020 Apr 1.
9
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.2019 年欧洲抗风湿病联盟/美国风湿病学会系统性红斑狼疮分类标准。
Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.
10
Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients.分析白细胞介素-17 和白细胞介素-23 以评估疾病活动度并预测活动性狼疮肾炎患者的治疗反应。
Immunol Lett. 2019 Jun;210:33-39. doi: 10.1016/j.imlet.2019.04.002. Epub 2019 Apr 17.

白细胞介素23在系统性红斑狼疮患者中的意义:与疾病活动和损伤指标的关系。

Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices.

作者信息

Haroon Maysa M, Hegazy Gehan A, Hassanien Mohammed A, Shaker Olfat, Hussein Wafaa H

机构信息

Department of Rheumatology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Clinical Biochemistry Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.

出版信息

Biologics. 2023 Jan 18;17:1-9. doi: 10.2147/BTT.S389021. eCollection 2023.

DOI:10.2147/BTT.S389021
PMID:36698375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9868139/
Abstract

BACKGROUND

Dysregulation of both cellular and humoral immune responses is central in systemic lupus erythematosus (SLE) pathogenetic mechanisms. Proinflammatory cytokines, such as interleukin 23 (IL23), and their roles in promoting such dysregulation have recently been highly considered. This research compared IL23 serum levels in 85 Egyptian SLE patients and 85 healthy controls. Then, IL23 level was correlated to various SLE disease parameters, disease activity, and damage indices.

RESULTS

IL23 serum levels were significantly elevated in SLE patients versus healthy individuals. Furthermore, IL23 levels were positively correlated with SLE disease activity index (SLEDAI) and were positively correlated with arthritis, seizures, consumption of complements (C3, C4), and with parameters of nephritis (hematuria, pyuria, casts, and proteinuria). A positive correlation was also found between IL23 levels and oral prednisolone dose.

CONCLUSION

IL23 has higher levels in the serum of SLE patients, and is correlated to activity of the disease, especially lupus nephritis. Further researchis needed to explore its exact role in SLE pathogenesis and whether it can be considered a potential biomarker or therapeutic target in SLE.

摘要

背景

细胞免疫和体液免疫反应的失调是系统性红斑狼疮(SLE)发病机制的核心。促炎细胞因子,如白细胞介素23(IL23),及其在促进这种失调中的作用最近受到高度关注。本研究比较了85例埃及SLE患者和85例健康对照者的IL23血清水平。然后,将IL23水平与各种SLE疾病参数、疾病活动度和损伤指数进行关联。

结果

与健康个体相比,SLE患者的IL23血清水平显著升高。此外,IL23水平与SLE疾病活动指数(SLEDAI)呈正相关,与关节炎、癫痫发作、补体消耗(C3、C4)以及肾炎参数(血尿、脓尿、管型和蛋白尿)呈正相关。IL23水平与口服泼尼松龙剂量之间也存在正相关。

结论

SLE患者血清中IL23水平较高,且与疾病活动度相关,尤其是狼疮性肾炎。需要进一步研究以探索其在SLE发病机制中的确切作用,以及它是否可被视为SLE的潜在生物标志物或治疗靶点。